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Trichotillomania (TTM) is a psychiatric disorder characterized by an irresistible urge to pull out
one’s hair. Currently there are no FDA approved treatments for TTM, which makes it difﬁcult
for clinicians to select an appropriate therapeutic plan. The clinical studies that have been
performed do not provide sufﬁcient or consistent evidence regarding which drug classes should
be administered. Unfortunately, most of the available data consist of case reports and clinical
trials with limited sample size. This review provides an overview of currently available clinical
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Clinical trialsliterature that targets TTM. A summary of clinical trials as well as case reports is provided. The
most common rating scales used for clinical assessment are also reviewed. The etiology of TTM
remains unclear. Studies that examine various neuroanatomical, neurobiologic, as well as
genetic factors associated with TTM are thoroughly discussed in this review. It is evident that
clear understanding of TTM is crucial to provide better recognition, assessment, and treatment
to patients of this disorder. Finally, despite research efforts for establishing pharmacological
options for treatment, it is clear that new targets are warranted in order to ensure a clinically
supported effective pharmacological approach to treat TTM.
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Originally described by Hallopeau in 1889, trichotillomania
(TTM) is a psychiatric disorder that is characterized by the
incontrollable urge to pull out one’s hair [1]. The preferred
term for this condition is ‘‘hair pulling disorder’’, as the word
‘‘trichotillomania’’ may be perceived with a negative connota-
tion [2]. It is currently classiﬁed under ‘‘Obsessive Compulsive
and Related Disorders’’ in the Diagnostic and Statistical
Manual of Mental Disorders, DSM-V [3]. Diagnostic criteria
include the following: continuously pulling out one’s own hair,
which results in hair loss, multiple attempts to reduce or stop
the hair pulling, clinically signiﬁcant impairment in daily func-
tioning (e.g. social gatherings, work), the hair pulling is not
associated with another medical condition, and it cannot be
explained by another mental disorder [3]. Previously in
DSM-IV, TTM was classiﬁed under impulse control disorders
(not classiﬁed elsewhere). Diagnostic criteria included an
increasing sense of tension right before pulling out the hair
or when resisting the urge, and pleasure, gratiﬁcation, or reliefwhen pulling out the hair [2]. As seen, this criterion was left out
of DSM-V as not all TTM sufferers experience these occur-
rences. Christenson et al. [1] described TTM sufferers as either
being aware or unaware of the hair pulling, or a combination
of both. These observations led to the TTM subtypes/styles
known as focused and automatic, respectively. Automatic hair
pulling usually occurs during sedentary activities such as lying
in bed, watching TV, or reading. Focused hair pulling, on the
other hand, occurs when hair is intentionally pulled out possi-
bly by searching for speciﬁc hairs to pull out. This more
focused pulling may allow the individual to distract themselves
from unwelcomed thoughts or feelings [4]. TTM has a lifetime
prevalence of 0.6% (according to DSM-III-R) for both gen-
ders. However, Christenson et al. [1] concluded that for
females the prevalence may be as high as 3.4% and 1.5% for
males. Sufferers typically pull from the scalp, eyebrows, and
eyelashes but may also pull from the face, axillary, and pubic
regions [1,5]. Some individuals participate in hair-related ritu-
als or behaviors once the hair is pulled out. These could
include rolling the hair between ﬁnger, running the hair over
the lips or through the teeth, biting the hair, and/or swallowing
the hair (trichophagia). Others reported pulling out speciﬁc
hairs based on characteristics such as texture, color, and length
[5]. The average age of onset occurs around 13 years, which
coincides with puberty [6].
TTM has also been thought to relate to, or overlap with
other psychiatric disorders including obsessive compulsive dis-
order (OCD), Tourette’s, and other impulsive disorders such
as nail biting and skin picking [1,2,7]. This overlap is seen in
TTM’s symptomatology including similar ritualistic behavior
and trigger cues as seen in body-focused repetitive behavioral
disorders (BFRBD) [2]. The similarities observed between
TTM and OCD include behaviors in response to urges, anxiety
relief after performing the behavior, and the repetitive nature
of the disorder [2]. Similarities with OCD also extend into
the treatment modalities used. According to Christenson
et al. [8] the lifetime prevalence of comorbid psychiatric disor-
ders in TTM patients was found to be as high as 81%, with
depression and anxiety subsequently reported as main con-
tributing comorbid disorders to TTM. TTM is a poorly under-
stood disorder. Behavioral therapy has proven effective in
many TTM patients; however, the use of pharmacotherapy
might be necessitated in some patients. Some individuals with
TTM may respond to pharmacotherapy with selective sero-
tonin reuptake inhibitors (SSRIs), as do those with OCD [2].
Limited knowledge exists regarding the neurobiological
basis of TTM. However, it is speculated that the disorder
probably involves multiple pathways and a complex interac-
tion between genetic, psychological, and social factors.
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trol, with the neurotransmitters serotonin, dopamine, as well
as GABA implicated in TTM [9]. Few brain imaging and
genetic studies have reported gray matter density differences
in various brain regions in TTM patients as compared to con-
trols [10–12]. The contribution of genetic factors has gained
research attention in the past decade, with reported mutations
in SLITRK1 and HOXB8 genes in TTM patients and experi-
mental animal models, respectively [13–15]. The current review
provides an overview of available studies that examined the
neurobiology and potential genetic determinants of the disor-
der as well as summarizes available literature regarding
reported clinical studies/cases of various pharmacotherapeutic
approaches. Future research directions that are needed for
understanding and management of this disorder are identiﬁed.Methods
A literature search was conducted using PubMed and Google
Scholar. The search spanned the period between 1989 and
February 2014. Key words, and their combinations, used for
the search were trichotillomania, hair pulling, hair pulling dis-
order, clinical trial, case report, neurobiology, genetic, and ani-
mal model. A total of 875 potentially relevant articles were
identiﬁed. The titles and abstracts of the articles were screened,
and 712 were excluded. Excluded articles were clinical reviews
as well as articles related to trichobezoar reports focused on
surgical treatment. The abstracts of the remaining 163 articles
were further examined, and 108 articles were excluded.
Exclusion criteria were non-English language of the article,
clinical trial of behavioral therapy approaches alone, and
duplicates. The remaining ﬁfty-ﬁve full text articles were
retrieved and included in this review, and thirteen articles
investigated the neurobiology, animal models, and genetic
aspects of TTM, while the remaining forty-two articles focused
on scoring scales and pharmacotherapeutic approaches of
TTM. The latter included both clinical trials as well as case
reports.Neurobiology of trichotillomania
Although TTM is classiﬁed according to DSM-V under obses-
sive compulsive and related disorders, the classiﬁcation of
TTM still remains controversial. As mentioned earlier, behav-
ioral therapeutic approaches have proven to be more effective
than pharmacotherapy in most patient cases. However, some
patient might require pharmacologic intervention. As will be
evident in later sections, pharmacotherapeutic approaches to
treating TTM include a wide variety of drug classes, primarily
antidepressants. So far, the FDA has not approved any phar-
macological treatment for TTM. Such lack of solid pharma-
cotherapeutic approaches might be partly attributed to our
deﬁcient understanding of the etiology and neurobiology of
the disorder. Current research has focused on neuroanatomical
studies that attempt to unravel any brain abnormalities that
might correlate with the symptoms of TTM. Grachev [10] used
MRI-based morphometric topographic parcellation to study
the differences in the human neocortex of 10 females with tri-
chotillomania compared to 10 females without (TTM). In this
study, researchers were interested in investigating volumetricchanges of the sensorimotor cortex, supplementary motor cor-
tex (juxtaparacentral lobule cortex) and operculum between
TTM and TTM-free participant. The study included 10
right-handed females with TTM that met DSM-IV criteria
for TTM, and did not have OCD, Tourettes, psychosis, major
depression, substance abuse or signiﬁcant medical or neurolog-
ical illnesses. The 10 female controls were also right-handed
and were similar in age and educational background. All sub-
jects had to have normal CBC, coagulation, and thyroid tests.
Control subjects though did not have a psychiatric, neurologic,
and physical examination. All 20 patients were free of psy-
choactive medications for at least 4 weeks. The average age
of TTM patients was 31.1 years and 28.5 years in control
patients. Researchers used MRI scans for brain images and a
standard 3-D brain coordinate system was used for positional
normalization. Statistically signiﬁcant volumetric differences
were found between the TTM patients and control groups in
the left inferior frontal gyrus, triangularis division, and the
right cuneal cortex. The volume of the triangularis division
was reduced by 27% while the right cuneal cortex was
increased by 40%. There were no statistically signiﬁcant differ-
ences in the total cerebral cortex volume. The increase in the
right cuneal cortex in TTM patients may stem from failure
of interactions between the visual and sensorimotor cortices
that cause increased neuronal stimuli to reach targets leading
to the repetitive or compulsive behavior seen in TTM [10].
Chamberlain et al. [11] investigated gray and white matter
abnormalities in terms of the whole brain in 18 individuals
with TTM as compared to 19 healthy individuals.
Participants were medication-free for >6 months and had no
previous diagnosis of depression or OCD. However, patients
with TTM showed signiﬁcantly higher Montgomery-A˚sbery
Depression Rating Scale (MADRS) scores and dysphoric
mood compared to healthy volunteers but neither demon-
strated clinically signiﬁcant depression in regard to the
MADRS score. Signiﬁcant differences were found in terms
of increased gray matter density in 3 clusters. These consisted
of the striatum (left putamen) and left amygdalo-hippocampal
complex, bilateral frontal regions (cingulate, supplemental
motor and superior cortices) and the left occipital and parietal
regions. No signiﬁcant differences were reported in white mat-
ter density. The ﬁndings of Chamberlain et al. [11] add more
evidence that link TTM and OCD together. Increased gray
matter has been reported in studies of OCD. The increased
gray matter may be due to neuroplastic changes that occur
when using brain regions involved in grooming, habit-
learning and motor skill training. Dysfunction or abnormali-
ties of the striatum, which is involved in habit learning and
automated action sequences, may disrupt the ability to per-
form choreographed grooming sequences. This ﬁnding impli-
cates the role of the basal ganglia in the development of
pathological habits. The abnormalities seen in the cingulate
and prefrontal lobes could be responsible for cognitive issues
seen in TTM patients. The abnormalities found in the
amygdalo-hippocampal region may cause the arousal and
emotional learning differences seen in hair pulling episodes.
This study provides baseline differences seen in different brain
regions of TTM patients. Some of the ﬁndings are inconsistent
with other available literature which leads to the need of future
studies that include more patients (including left-handed indi-
viduals to see whether there are differences in implicated brain
regions), screening not only for depression but also for anxiety,
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the neuroimaging. Other researchers have shown that neurons
found in the anterior dorsolateral regions of the caudate–puta-
men are activated during grooming movements [16]. The
graphical abstract summarizes the brain regions implicated in
the pathology of TTM.
A recent study by Odlaug et al. [12] examined impaired
response inhibition and cortical thickness in TTM patients,
their unaffected ﬁrst degree family members, and control sub-
jects. The study reported a signiﬁcant impairment of response
inhibition performance in TTM patients as compared to con-
trols. In addition, a signiﬁcant increase in cortical thickness
was observed in TTM patients and their relatives compared
to controls. The areas affected by the change were primarily
localized in regions controlling response inhibition including
the right inferior/middle frontal gyri, left precuneus, left supe-
rior temporal cortex, and right lingual gyrus.
Although TTM is currently classiﬁed under obsessive com-
pulsive and related disorders, previous research has focused on
its relevance to impulse control disorders (ICDs). Extensive
research has been conducted that focused on neurobiological
role of various neurotransmitters in the pathology of ICD
and their relevance to TTM. Serotonin (5-HT) has been impli-
cated in OCD as well as ICD because of its role in impulse con-
trol as well as repetitive motor behaviors. Animal studies have
previously shown that serotonin depletion leads to impulse
choices and motor behavior [17,18]. The activation of seroton-
ergic systems using SSRIs has been explored as a treatment
option for TTM patients. However, as seen in later sections
of the review, data from various clinical studies and case
reports show mixed results and the efﬁcacy of SSRIs for
TTM treatment remains unclear. Dopaminergic systems are
implicated in both OCD and ICD. The use of antipsychotic
agents that block dopaminergic D2 receptors has been effective
in the management of a subset of TTM patients, as discussed
in later section [19–21]. The inhibitory neurotransmitter
GABA has been functionally and anatomically connected to
dopaminergic systems. A retrospective study by Nikolaus
et al. [9] demonstrated regulation of dopamine by both
GABA and 5-HT neurotransmitters in pooled patients with
OCD and anxiety disorders. Both GABA and 5-HT exert inhi-
bitory effect on dopamine, and their reduction leads to
enhanced dopaminergic activity in the mesolimbic system,
playing a role in the development of anxiety and obsessive
compulsive disorders [9]. The recent studies that demonstrated
efﬁcacy of the glutamate modulator N-acetylcysteine (NAC) in
TTM patients have drawn research attention to the role that
glutamate might play in the pathophysiology of TTM [22,23].
It is evident that data available so far suggest that a com-
plex interaction between various neurobiological systems
might play a role in the pathophysiology of TTM, and further
studies are certainly warranted.Genetics studies
In addition to neuroanatomical studies, research efforts have
also emphasized the role of genetics in TTM. Abelson et al.
[13] reported a 1 bp deletion in SLITRK1 gene in a boy with
Tourette’s syndrome and attention deﬁcit hyperactivity disor-
der (ADHD). The boy’s mother carried the same mutation
and suffered from severe TTM. In a 2006 letter to the editorZuchner et al. [14] proposed that a sequence variation on
SLITRKI may play a role in the development of TTM. The
research group sequenced the whole SLITRKI gene of 44
TTM families where at least one member met DSM-IV criteria
for TTM. Researchers discovered two distinct non-
synonymous changes in two independent TTM subjects.
Both occurred between the second LRRCT domain and the
transmembrane domain of SLITRKI. Zuchner et al. [14] sug-
gest that mutations in this position may be associated with
TTM without Tourettes since mutations that were previously
observed by Abelson et al. [13] were located in a different area
of the protein. In the study 2192 non-TTM Caucasian controls
were screened for this variation and none were found.
Researchers concluded that these sequence variations are sig-
niﬁcantly associated with the TTM phenotype.
The other gene implicated in TTM is the HOXB8 gene.
Animal studies conducted by Greer and Capecchi reported
that variations in the HOXB8 gene of mice result in excessive
grooming that leads to bald sports and skin lesions. They sug-
gest a link between this behavior and the behavior seen in
TTM [15]. Many brain areas are involved in initiating a cas-
cade of signals that lead to movements seen in grooming ses-
sions. These brain regions include the brainstem and
striatum. Excessive grooming has been observed in OCD and
TTM but inﬂuential genes in these two disorders have not been
elucidated. Greer et al. point out that mice that are homozy-
gous for a loss-of-function mutation in HOXB8 show excessive
grooming behavior. The hox genes are responsible for embry-
onic development, hair formation in adult mice, and matura-
tion of breast tissue in pregnant females. The HOXB8
homozygous mutant mice not only demonstrate excessive
self-grooming behavior but also excessively groom control
cage mates [15]. Researchers videotaped individual mice from
7 littermate pairs of one wild and one mutant for a 24-h period
in order to see under what conditions the HOXB8 mutants
removed their hair. Each mouse was scored for eating, drink-
ing, sleeping and grooming. All aspects were similar in wild
type and mutants except for grooming behaviors which
showed that grooming time was doubled in the mutants com-
pared to the wild type. The mutants also initiated grooming
more frequently than controls. The researchers point out that
the mutant mice groomed all parts of their body which is dif-
ferent from TTM where sufferers focus their pulling on speciﬁc
areas of the body such as the scalp, eyebrows/lashes, and pubic
area. Mutant mice also spent about one hour less time sleeping
than controls as this hour was devoted to grooming [15]. When
mutants and wild type mice were housed together, ‘‘the wild
type showed large bald areas on their back and tops of their
heads’’. Following video analysis, it was obvious that the wild
type mice were being groomed by the mutants.
Greer and Capecchi [15] conducted a transgenerational
study in which they backcrossed F1 generation HOXB8
mutants for 5 generations. The grooming behavior was seen
in all homomutants using the home cage and misting-
induced grooming assay. The mutants showed a 2-fold
increase in grooming behavior during the induced-grooming
assay compared to controls. Hair removal and skin lesions
were visually observed in the mutants as well. Using an RT-
PCR assay, researchers showed the presence of the HOXB8
gene in the adult mouse CNS. Expression was found in the
olfactory bulb, basal ganglia, hippocampus, cortex, cerebellum
and the brainstem of the wild type adult.
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‘‘OCD circuit’’ which includes the orbitofrontal cortex, the
anterior cingulate cortex and the caudate nucleus. Abnormal
metabolic activity is seen in OCD patients within the cells of
this circuit [24]. Overall, Greer et al. state that the excessive
grooming behavior observed in mice without HOXB8 function
is very similar to that seen in TTM. They argue that due to the
expression pattern of HOXB8 in the CNS and the behavior
analysis, TTM should be classiﬁed as an OC-spectrum disorder.
Based on the information presented, they believe TTM may be
caused by ‘‘misregulation of an innate autogrooming behavior
that results in excessive repetition of this behavior’’. Further
studies are needed to determine whether human TTM patients
show the mutations reported in the HOXB8 gene [15].
Our current understanding of the neurobiology of TTM is
rather incomplete. Despite the fact that most available studies
have focused on neuroimaging, the exact neural circuitry
involved in the disorder is not entirely delineated. The overlap
between TTM and other impulsive–compulsive disorders
should be further investigated through examining the neurocir-
cuits associated with impulsive and compulsive behavior. Such
studies might help identify various subtypes of TTM as they
relate to impulse or compulsive disorders. Additional imaging
studies are needed that include unaffected family members of
TTM patients. Coupled to imaging studies, future research
should include investigation of receptor distribution and bind-
ing in TTM patients as compared to controls. Serotonin, nora-
drenergic, dopaminergic, glutamatergic, and other receptors
involved in effective processing, impulsivity, and compulsion
could be examined for abnormal binding using radioligand
PET. Additional studies are needed to examine the role of glu-
tamatergic dysfunction in animal models of TTM as well as in
TTM patients, especially that recent data show that abnormal-
ities in glutamatergic function might play a role in OCD patho-
genesis. Furthermore, the role of biological and environmental
risk factors in the pathogenesis of TTM needs to be studied.
Animal models of trichotillomania
Animal models are important for studying the pathology of
various human diseases and disorders [25]. They are valuable
tools to systematically study innumerable disorders as well to
investigate potential treatments in a preclinical setting.
However, there are a few limitations associated with develop-
ing an animal model, including the fact that most disorders do
not develop spontaneously in the animal being studied and
must be induced [25]. However, there are certain behaviors
that do develop spontaneously in conﬁned animals that can
be used to mimic human disorders. The following represent
examples of each type of animal model that can be used in
studying TTM in experimental animals.
Garner et al. [26] proposed the barbering mouse model as
an experimental model to investigate treatment efﬁcacy for
TTM. Barbering is a spontaneous abnormal behavior that
commonly develops in caged animals. Researchers believe that
because barbering is an abnormal behavior seen in laboratory
mice, and because it occurs spontaneously, such model would
be sufﬁcient to mimic TTM. Results showed that the demogra-
phy is similar to TTM (age and gender). It also showed similar
phenomenology (pulling from scalp, around the eyes, and gen-
itals) and etiology [26].Greer and Capecchi [15] demonstrated that HOXB8
homozygous mutant mice show an increase in grooming
behaviors. These mice display excessive hair removal and
increased amount of time spent grooming compared with wild
type mice. They also initiate grooming behaviors more often
than controls, and groom their wild type cage mates. Greer
and Capecchi [15] suggest that TTM may occur due to a mis-
regulation of a natural autogrooming behavior that results in
the excessive repetition of this behavior that is characteristic
of the disorder.
Both animal models show similar characteristics to that of
TTM. Either one can be a useful model when trying to deter-
mine the efﬁcacy of treatments for TTM. However, further
studies of these models with regard to neurobiology, imaging
changes in brain structure and function, and correlation to
changes in TTM patients are warranted in order to validate
these models. Establishing a reliable experimental model of
TTM will certainly provide a valuable tool for evaluating pre-
clinical pharmacotherapeutic options for TTM patients.
Commonly used rating scales
Assessment of TTM is a challenging task, as it requires inte-
grating information from multiple sources, as well as the fact
that it might heavily rely on patient self-assessment, which
can be challenging, particularly in children. Initial diagnosis
of the disorder certainly depends heavily on accurate assess-
ment. Several assessment scales have been developed over the
past decade. These assessments include symptoms’ presenta-
tion, severity, functional impairment, as well as comorbidity.
The following section summarizes a few of the commonly used
clinical scales for the assessment of TTM.
NIMH trichotillomania questionnaire
This questionnaire consists of 2 scales, the NIMH
Trichotillomania Severity Scale (NIMH-TSS) and the NIMH
Trichotillomania Impairment Scale (NIMH-TIS). These scales
stemmed from the Yale-Brown Obsessive Compulsive scale
(Y-BOC scale). NIMH-TSS contains ﬁve questions regarding
the average time the patient spent pulling, time spent pulling
on previous day, ability to resist the urge to pull, resulting dis-
tress, and daily interference. The scoring range is from 0 to 25
and higher scores indicate greater severity. The NIMH-TIS
classiﬁes the level of impairment from no impairment to severe
impairment using a 10-point scale. This scale takes into
account level of embarrassment as well as interference of daily
activities caused by noticeable hair loss. Again, a higher score
indicates greater impairment [27].
Clinical Global Impression (CGI) scale
The CGI is a tool used in psychiatry that has the clinician rate,
their current patient’s illness severity, improvement, and ther-
apeutic response based on past experiences with patients who
also had the disease/disorder. The severity portion is rated
on a 7-point scale with higher points corresponding to the
most severely ill (CGI-S). The improvement portion (CGI-I)
is also rated on a 7-point scale with higher numbers indicating
that the patient is very much improved. The therapeutic
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account both the level of symptom resolution and impairment
due to side effects [28].
Massachusetts General Hospital-Hair Pulling Scale (MGH-
HPS)
This is a self-report scale that measures the urge to pull, actual
hair-pulling, and the consequences of hair-pulling. It is rated
on a scale from 0 to 4 with higher numbers corresponding to
negative outcomes. The section regarding the urge to pull takes
into account the frequency and intensity of the urges, and the
ability to control the urges. The second section, which rates the
actual pulling on a 0–4 scale, takes into consideration how
often the patient pulled their hair, the frequency of resisting
the urge, and how often the patient was able to control the
hair-pulling. For the ﬁnal section regarding the consequences
of hair-pulling, the patient is asked how uncomfortable or dis-
tressed the hair-pulling made them feel [29].
Milwaukee Inventory for Styles of Trichotillomania-Adult
Version (MIST-A)
This scale focuses on separating subtypes into 2 distinct
classes, automatic and focused. ‘‘Automatic’’ pulling refers
to a patient who is not aware that they are pulling out their
hair while ‘‘focused’’ pulling refers to a patient who is inten-
tionally pulling out their hair. The scale is comprised of 15
statements divided into 10 regarding focused pulling and 5
regarding automatic pulling. Responses to these statements
will help classify patients into 1 of the 2 subtypes [30].
Psychiatric Inventory Trichotillomania Scale (PITS)
The PITS is a tool that is administered by a physician that
rates the symptoms of hair pulling during the previous week.
It is a 6-item scale and each item is rated from 0 to 7 with
higher numbers corresponding to greater severity. Items being
assessed in this scale include the number of hair pulling sites,
time spent pulling and thinking about pulling, resistance to
urges, distress, and interference with daily activities [31].
Hamilton Anxiety Rating Scale (HAM-A)
The HAM-A is a clinician-rated scale that measures the degree
of anxiety. It consists of 14 items, each being scored from 0 to
4 with 4 denoting severe. Each item is a phrase about the
patient’s feelings followed by a list of symptoms. Total score
ranges from 0 to 56 with higher numbers indicating very severe
anxiety [32].
The availability of multiple TTM-speciﬁc rating scales has
been crucial in order to properly assess individuals with the
disorder. These scales have been instrumental to clinical trials
as they provide an objective assessment of the efﬁcacy of the
proposed therapy and patients’ response to treatment.
However, currently available assessment tools do suffer from
some shortcomings. Physician-rated scales are liable to inter-
rater variability. While self-reported instruments are crucial,
particularly in the initial baseline assessment of symptoms,
many TTM patients lack awareness of hair pulling. Inaddition, self-monitoring may induce reactivity responses in
the patients. Advancement in digital photography might help
researchers and contribute to future accurate quantiﬁcation
of hair density in TTM patients.
Clinical studies/cases for pharmacotherapeutic treatment of
TTM
So far the FDA has not approved any pharmacological treat-
ment for TTM. Cognitive behavioral therapy (CBT) and habit
reversal therapy (HRT) proved to be effective therapeutic
interventions in many cases of TTM. While behavioral thera-
peutic approaches of TTM are not the focus of this review,
it is important to note that several randomized controlled trials
have reported behavioral therapy to be effective for the man-
agement of TTM patients. On the other hand, available litera-
ture regarding pharmacotherapy of TTM reports equivocal
outcomes. Overall, most research studies are comprised of
small case reports, small size trials, and with heavy emphasis
on behavioral therapy. Studies that explored pharmacological
treatment of TTM have spanned a variety of drug classes,
ranging from antidepressants, antipsychotics, to CNS stimu-
lants, and others. The next few paragraphs summarize the cur-
rent literature for TTM pharmacotherapy.
CNS stimulants
Very few clinical studies have focused on CNS stimulants as
possible treatment options for TTM. Two studies have sug-
gested that the symptom often seen in TTM patients, the irre-
sistible urge to pull out one’s hair is indicative of dysfunction
of the inhibitory neuronal circuits [33,34]. One study reported
that TTM patients (n= 17) showed statistically signiﬁcant
impaired inhibitory control when compared to non-TTM
patients (n= 20) [32]. Aron et al. [35] correlated the disrup-
tion in stop signal, which is observed in cases of TTM, to a
dysfunction in the right inferior frontal gyrus, which causes
an increase in stop signal response. Chamberlain et al. [36]
tested the response inhibition of atomoxetine (selective nore-
pinephrine reuptake inhibitor) and citalopram (SSRI) on the
norepinephrine and serotonin systems, respectively. The goal
of this experiment was to deﬁne the contribution of the sero-
tonin and norepinephrine systems to response inhibition and
probabilistic learning. Researchers reported that inhibition of
serotonin reuptake, by way of citalopram, had no effect on
response inhibition while norepinephrine reuptake inhibition
improved response inhibition in healthy volunteers. Due to
these observations, researchers have implicated nore-
pinephrine and inhibitory system dysfunction in the patho-
physiology of TTM with the prospect of utilizing CNS
stimulants that up-regulate NE system to manage symptoms
of TTM [37]. One such study examined the effects of moda-
ﬁnil on motor inhibitory control in TTM [37]. Researchers
believed that due to modaﬁnil’s possible effects on nore-
pinephrine transmission, this medication might improve
impaired inhibitory control seen in TTM patients. In this 2-
week crossover double-blind, placebo-controlled study, mod-
aﬁnil did not show any signiﬁcant improvement effects on
inhibitory control or cognition enhancement [37]. Similarly,
Golubchik et al. [38] performed a study to assess the efﬁcacy
and tolerability of methylphenidate in the treatment of TTM
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niﬁcant improvement in the severity of TTM was observed. A
case report involving a 30 year-old white female with an 11-
year history of TTM that received fenﬂuramine 20 mg
showed a drastic decrease in the urge to pull her hair [39].
It is obvious that there is limited literature regarding the
use of CNS stimulants in the treatment of trichotillomania
making it difﬁcult to conclude whether they offer any beneﬁt
in the management of the disorder. More controlled trial
studies are certainly needed.
Antiepileptic drugs
Due to TTM being classiﬁed by DSM-IV as an impulse control
disorder, it is thought that mood stabilizers may be efﬁcacious
in its treatment [40]. The effectiveness of topiramate, an
antiepileptic drug that Blocks neuronal voltage-dependent
sodium channels, enhances GABA(A) activity, antagonizes
AMPA/kainate glutamate receptors, and weakly inhibits car-
bonic anhydrase enzyme, and oxcarbazepine (that primarily
acts by blocking voltage-sensitive sodium channels) might be
attributed to the inhibition of the glutamatergic pathway, that
is implicated in compulsive and repetitive behaviors. One of
the mechanisms of actions of valproic acid is the modulation
of the GABA system, which is responsible for ‘‘calming’’ the
nerves down. Topiramate has been used in the treatment of
other impulse control disorders including binge-eating, skin-
picking, pathological gambling, and kleptomania. However,
other recent studies have shown that anticonvulsants are inef-
fective in treating impulse control disorders [41,42]. A case
report of an obese patient with binge eating disorder and
comorbid TTM was treated with oxcarbazepine 1200 mg/day.
Complete cessation of TTM symptoms was seen after
6 months of treatment. A follow-up visit after 9 months
showed no relapse in hair-pulling and more stable mood
[43]. Another case report of a 9 year-old African American
girl, with several comorbid psychiatric disorders, experienced
a dramatic reduction of TTM symptoms after an increase in
her valproic acid medication. Valproic acid acts primarily by
blockade of voltage-gated Na+ channels and by increasing
availability of gamma-aminobutyric acid (GABA) [44]. The
patient was already treated with valproic acid for seizures.
When the dose of valproic acid was increased to control the
seizure attacks, it was noted that the urge to pull hair signiﬁ-
cantly decreased. Lochner et al. [40] conducted an open-
label, ﬂexible dose study that assessed the efﬁcacy of topira-
mate in 14 adults with TTM. Although topiramate led to a
reduction in hair-pulling as the primary outcome measure,
there was no statistical signiﬁcance.
Due to the lack of evidence-based support, it is hard to
decide whether antiepileptics are useful in the treatment of
TTM. It is also apparent that the randomized control trials
that are available all suffer from a small sample size.
Opioid antagonists
Opioid antagonists are used clinically in the treatment of etha-
nol dependence, pathological gambling, and adult kleptoma-
nia [45]. These disorders were classiﬁed in DSM-IV as
impulse control disorders, along with trichotillomania.
Currently, trichotillomania (hair-pulling disorder) is classiﬁedunder obsessive–compulsive and related disorders along with
hoarding, excoriation (skin-picking) disorder, substance-/
medication-induced obsessive–compulsive and related disor-
der, and obsessive–compulsive and related disorder due to
another medical condition. Gambling is listed under substance
related and addictive disorders and kleptomania is classiﬁed
under disruptive, impulse-control, and conduct disorders.
The main characteristic observed in TTM patients is hair-
pulling; despite the association of hair-pulling with detrimental
effects, including pain, the patient typically disregards these
consequences [45]. These observations led researchers to spec-
ulate that opioid system dysfunction may be implicated in
TTM.
A 10-month long pilot study of 14 children with TTM eval-
uated the efﬁcacy of the opioid receptor antagonist, naltrexone
on TTM. Patients showed a statistically signiﬁcant reduction
in CGI-S, hair-pulling, frequency and urge intensity of hair-
pulling [46]. On the other hand, Grant et al. investigated the
efﬁcacy of naltrexone in a double-blind placebo controlled trial
with 51 TTM patients randomized to naltrexone or placebo.
The study showed no difference between naltrexone and pla-
cebo in hair pulling frequency, but signiﬁcant improvement
of cognitive ﬂexibility was observed [46].
Since there are only 2 studies that have tested the efﬁcacy of
the opioid antagonist, naltrexone, with obvious variable out-
comes, there is a need for more studies to provide a more con-
sistent result. Since both studies showed different results it is
difﬁcult to draw a conclusion about whether naltrexone should
be used for the treatment of TTM.
Glutamate modulators
Glutamate is the main excitatory neurotransmitter in the CNS,
and excessive amounts of glutamate are known to cause neu-
ronal damage. Since glutamatergic dysfunction has been seen
in patients with OCD, a disorder that may be linked to
TTM, researchers believe that using glutamate modulators,
such as N-acetylcysteine (NAC), may help restore glutamate
concentrations in the brain to a lower level [22]. NAC is an
antioxidant most commonly known for its hepato-protective
effects. NAC is metabolized into cysteine, a substrate for the
cysteine-glutamate anti-porter that allows for the uptake of
cysteine. The uptake of cysteine causes the reversal transport
of glutamate into the extracellular space. This in turn stimu-
lates inhibitory metabotropic glutamate receptors reducing
the synaptic release of glutamate [22].
Following a case report of using NAC in a TTM patient,
researchers conducted a 12-week, double-blind, placebo-
controlled trial in order to determine the efﬁcacy and tolerabil-
ity of NAC in adult patients with TTM [22]. Patients in the
NAC group showed statistically signiﬁcant improvement for
hair pulling [22]. However, more studies are needed to deter-
mine the efﬁcacy of N-acetylcysteine in the treatment of
TTM. Future studies should include a large sample size and
a long-term study interval.
Bloch et al. [23] conducted a double-blind placebo con-
trolled study that investigated the efﬁcacy of NAC as an
add-on treatment for TTM in a pediatric population. A change
in severity of TTM was the primary outcome of the study, and
the results revealed no signiﬁcant difference between NAC and
placebo-treated patients.
Table 1 Summary of clinical studies/case reports of potential pharmacotherapy of trichotillomania.
Study Agent/drug Subjects Dosage and treatment duration Assessment measure Main outcome Side eﬀects
Eﬀects of acute
modaﬁnil on
cognition in
trichotillomania [37]
Modaﬁnil (CNS
stimulant)
18 patients
(14 female and 4 male),
with a mean age of 33.4
200 mg for the 1st week and
placebo the second week
Inhibitory control
and cognitive
enhancement
No signiﬁcant
improvement
Not stated
Methylphenidate
treatment
in pediatric patients
with
attention-deﬁcit/
hyperactivity
disorder and comorbid
trichotillomania: a
preliminary
report [38]
Methylphenidate
(CNS stimulant)
Nine children
(6 female and 3 male),
aged 6–18 years,
were treated with
methylphenidate
0.5–0.7 mg/kg for 12 weeks Severity of TTM and
tolerability of treatment
No signiﬁcant
improvement
in severity of TTM
Decrease in appetite
Headache
Excessive preoccupation
with one’s hair
Abdominal pain
Motor tic exacerbation
Fenﬂuramine and
trichotillomania [39]
Fenﬂuramine
(CNS stimulant)
Case report of a 30 year
old female received
fenﬂuramine after an
11 year history of TTM.
The patient was partially
responsive on
ﬂuoxetine and sertraline
Fenﬂuramine, 20 mg,
was added to the
daily regimen of
sertraline (100 mg)
and alprazolam (1 mg).
Patient continued
on fenﬂuramine alone
for remission
Urge to pull hair Signiﬁcant decrease in
urge to pull hair
Not stated
Oxcarbazepine for the
treatment of
trichotillomania [43]
Oxcarbazepine
(anticonvulsant,
mood stabilizer)
Case report of a 43-year-old
woman with binge eating
disorder and comorbid TTM
Flexible dosing of
oxcarbazepine
up to 1200 mg/day
Hair pulling and
eating behavior
The patient reported
improvement in hair
pulling and eating
behavior after 6 months
of treatment, and
with no relapse after
9 months
Sleepiness
Confusion
Asthenia
Trichotillomania: a
case response to
valproic acid [44]
Valproic acid
(anticonvulsant,
mood stabilizer)
Case report of a 9 year-old
African American girl,
with several comorbid
psychiatric disorders
Patient was already on
valproic acid for seizures.
Dosing regimen was
increased with trough levels range
between 115 and 125 mg/100 mL
TTM symptoms and
urge to pull hair
Patient reported
a signiﬁcant decrease
in urge to pull hair and an
increase in hair growth
Not stated
Topiramate in the
treatment of
trichotillomania; an
open-label pilot study
[40]
14 adults (13 female and 1 male),
aged 19–43 years, for the
treatment of TTM
A 16-week open-label,
ﬂexible dose study; the
initial dose was 25 mg every
evening for 7 days. On day 8,
the dose was increased
to 50 mg and increased
again to 75 mg on day 15.
Dose increases of 25 mg
were allowed at the beginning
of weeks 4–7 and a ﬁnal
increase in weeks
8–12 to a maximum
of 250 mg
TTM severity by
the MGH-HPS
A non-signiﬁcant
reduction in TTM severity
Paraesthesia
Speech/language diﬃculty
Increased anxiety
Weight loss
Nausea
Headache/migraine
Insomnia
Myalgia
Depressed mood
Double/blurry vision
Dry mouth
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An open-label pilot
study of naltrexone in
childhood-onset
trichotillomania [45]
Naltrexone (opioid
antagonist)
Nine (9) girls and
5 boys (mean age of 9)
with TTM as primary
diagnosis were included
in a 10 month pilot study.
Only those receiving
naltrexone as monotherapy
were included. Exclusion
criteria were those receiving
concomitant CBT or
psychotherapy and
those with other diagnoses
Naltrexone started at
25 mg/day and was
increased to a
maximum of 100 mg
(based on symptoms)
after 1 week
CGI-S, hair pulling,
frequency, and
intensity of hair pulling
A statistically
signiﬁcant reduction in
all TTM measured
parameters was observed
None experienced
The opiate antagonist,
naltrexone, in the
treatment of
trichotillomania:
results of a double-blind,
placebo-controlled study [46]
Naltrexone
(Opioid antagonist)
Fifty-one (51) TTM patients,
males and females,
mean age of 32.7
Patients were given
naltrexone over an
8 week period. Dose
started at 50 mg/d, and
increased to 10 mg/d
after 2 weeks, then to
150 mg/d after 4 weeks
TTM severity using
MGH-HPS and
cognitive function
using the
intradimensional
/extradimensional
diﬀerences between c
No signiﬁcant
eﬀect on hair pulling
Naltrexone group
showed signiﬁcant
improvement of
cognitive ﬂexibility
Mild sedation
No signiﬁcant eﬀect
on liver function
N-Acetylcysteine,
a glutamate modulator,
in the treatment of
trichotillomania: a
double-blind,
placebo-controlled
study [22]
N-Acetylcysteine
(NAC) glutamate
modulator antioxidant
Fifty (50) adults
(45 women and 5 men),
aged 18–65 years old
Patients were given
NAC 1200 mg/d, or
placebo, for 6 weeks.
At week 6, the dose was
increased to 2400 mg/d
for the next 6 weeks
TTM severity by
MGH-HPS, CGI,
PITS psychosocial
functioning,
depression, and anxiety
Signiﬁcant decrease
in hair pulling
(MGH-HPS and PITS)
Nausea
Diarrhea
Cough
N-Acetylcysteine as an
add-on treatment for
TTM in children and
adolescents [23]
N-Acetylcysteine (NAC)
Glutamate modulator
Antioxidant
Thirty-nine (39)
children/adolescents
between the ages of 8 and
17 years old who had
a primary diagnosis of TTM,
but no other psychiatric,
mental, developmental disorder,
asthma, or substance use
disorder All participants
were receiving pharmaco-
and psychotherapy that started
>3 months prior to the
trail and continued the
therapy during the trial
NAC was titrated over
the course of 4 weeks to
a maximum dose of
2400 mg. The study
continued for 12 weeks
TTM severity
MGH-HPS, TSC-C, P),
NIMH-TSS, MIST-C,
CGI (Clinical Global
Impression) depression,
anxiety, and adverse eﬀects
No signiﬁcant
improvement
in hair pulling in
response to NAC
treatment
Nausea, diarrhea, fatigue,
insomnia, rash, depression,
and diﬃculty in swallowing
the pills were reported by
both NAC and placebo
groups. Nausea was more
signiﬁcantly reported in
the placebo compared to the
NAC group
(continued on next page)
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Table 1 (continued)
Study Agent/drug Subjects Dosage and treatment duration Assessment measure Main outcome Side eﬀects
Dronabinol, a cannabinoid
agonist, reduces hair
pulling in TTM [47]
Dronabinol Synthetic
D9-Tetrahydrocannabinol
14 patients (all female),
aged 18–65, were started
on dronabinol
Dronabinol administered
at 2.5 mg/d for 3 weeks,
and at week 3, the
dose was increased
to 5 mg/d for 3 weeks,
and then increased
to 10 mg/d at week
6 for 3 weeks, and
to 15 mg/d at week 9 for 3 weeks
TTM severity by
MGH-HPS and
CGI scale neurocognitive
tests
Statistical signiﬁcant
improvement in TTM
score, with no signiﬁcant
eﬀect on cognitive functions
No signiﬁcant adverse
eﬀects on cognition
reported
Escitalopram treatment
of trichotillomania [48]
Escitalopram
Antidepressant; SSRI
20 women, aged
18–60
Patients started on
escitalopram 10 mg/day
for 4 weeks, then the dose
could be increased to
20 mg/day based on clinical
responsiveness, and at
8 weeks the dose
was increased to 30 mg/day
TTM severity by TSS
and ITT
Signiﬁcant decrease
in TTM severity
Nausea
Insomnia
Fatigue
Lethargy
Sweating
Dilated pupils
Decreased libido
Orgasmic
Dysfunction
Bruising
Skin rash
Use of the selective
serotonin reuptake
inhibitor citalopram
in the treatment of
trichotillomania [49]
Citalopram
Antidepressant; SSRI
14 patients, not currently
receiving a SSRI,
13 female and 1 male,
aged 20–45
Citalopram was given
initially at 20 mg/day
and was increased
every 2 weeks, based
on clinical response,
to a maximum of 60 mg/day
TTM severity by Y-BOCS,
NIMH-OCS,
and CGI scale depression
Signiﬁcant reduction in
TTM severity
and comorbid depression
Headache
Diminished sexual desire
Sleepiness/sedation
Tension
Orgasmic
dysfunction
Decreased salvation
Nausea/vomiting
Tremor
Weight gain
Constipation
Weight loss
Orthostatic dizziness
Palpitations/tachycardia
Increased yawning
A long-term, double-blind,
placebo-controlled crossover
trial of the eﬃcacy of
ﬂuoxetine for trichotillomania [50]
Fluoxetine
Antidepressant; SSRI
16 patients
(14 women and 2 men),
aged 20–68
Patients were initially
given ﬂuoxetine 20 mg/day
that was increased to
80 mg/day over 12 weeks.
The study started with
a 2-week placebo
washout period,
followed by a 12-week
treatment period, 5-week
washout period, and
a 12-week crossover
treatment period
Severity of TTM, severity
of hair pulling, urge
to pull, days of hair
pulling, and
daily hair counts
No signiﬁcant
eﬀect of ﬂuoxetine
on severity of TTM
Nightmares
Insomnia
Dizziness
Irritability
Anxiety
Nausea
Diarrhea
Constipation
Anorgasmia
Decreased appetite
Increased weight
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Bupropion XL for the
sustained treatment of
trichotillomania [51]
Bupropion Antidepressant;
Dopamine,
norepinephrine-reuptake
inhibitor
Case report, 35 year
old with 8-year history
of TTM had been treated
with psychotherapy,
pharmacotherapy,
and hypnosis,
in addition to
Bupropion given at
150 mg/day, was
increased after 1 week
to 300 mg/day,
and again after
2 weeks to 450 mg/day
Frequency of hair pulling Patient reported
complete cessation
of hair pulling after
2 weeks of
bupropion treatment
Decreased appetite
Weight loss
A case of
trichotillomania
successfully treated
with clomipramine [52]
Clomipramine
Antidepressant;
Tricyclic antidepressant
Case report, 17-year-old
girl with TTM initially
underwent psychotherapy
for treatment with no avail
Patient prescribed
clomipramine,
30 mg/day for 2 weeks
Urge to pull hair Patient reported the
ability to resist
the urge to pull out hair
after 2 weeks of
treatment
Not stated
Lithium treatment of
chronic hair pulling [39]
Lithium Antimanic Ten patients Lithium 900–1500 mg
administered for
2–14 months
Hair pulling and
hair regrowth
Eight patients reported
decreased hair pulling
and mild-moderate
hair growth
Increased thirst
Weight gain
Tremor
Lithium treatment of
trichotillomania with
comorbid bipolar II
disorder [54]
Lithium Antimanic A case report of a
26-year old woman
with TTM, exacerbated
postpartum, bipolar
II disorder, panic disorder,
and cannabis dependence.
She had been previously
prescribed various
medications for treatment
including sertraline,
paroxetine, risperidone,
and quetiapine
Lithium treatment
was initiated, then
the dose was slowly
increased to 900 mg
TTM severity TTM symptoms improved
within 4 days. Complete
cessation of that hair
pulling urge was
reported following
7 months treatment
with a higher lithium dose
Not stated
Lithium treatment of
trichotillomania with
comorbid bipolar II
disorder [54]
Lithium Antimanic A case report of a
27-year old pregnant
woman, with TTM and
co-morbid bipolar II
disorder
Patient treated
with lithium
TTM severity and
urgency to pull hair
A signiﬁcant reduction
in TTM score and
urgency to pull her hair
was observed
after 6 weeks of treatment
Not stated
A randomized, double-
blind, placebo-
controlled trial of
olanzapine in the
treatment of
trichotillomania [20]
Olanzapine Antipsychotic Twenty-ﬁve (25) patients
(17 women and 8 men),
aged 18–65 years,
randomly assigned
The primary eﬃcacy
measure was the
CGI-I scale
Flexible dose olanzapine
(2.5–20 mg/d) or placebo.
Patients were given 2.5 mg/d
for weeks 0–3, up to 5 mg/d
for weeks 4 and 5, up to
10 mg d for weeks 6 and 7,
and up to 20 mg/d for
weeks 8–12
TTM severity Olanzapine signiﬁcantly
reduced TTM severity
as compared to
placebo group
Dry mouth
Fatigue
Increased appetite
Headache
Weight gain
(continued on next page)
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Table 1 (continued)
Study Agent/drug Subjects Dosage and treatment duration Assessment measure Main outcome Side eﬀects
The potential role
of haloperidol in
the treatment of
trichotillomania [19]
Haloperidol First
generation antipsychotic
Nine (9) patients
(all women, with an
average age of 32.8 years)
Six patients who had
a partial response
or no response to SSRIs
were treated with
haloperidol and an
SSRI. The three other
patients only received
haloperidol. Doses ranged
from 0.25 mg/d to 2 mg/d.
Four patients received
ﬂuoxetine as their SSRI,
1 received paroxetine, and
another received ﬂuvoxamine
Researchers used the
Structured Clinical
Interview for DSM-III-R
and a modiﬁed Minnesota
Trichotillomania Assessment
Inventory to evaluate
patients. Response to
treatment was based on
descriptions of hair
pulling, quantity of hair
pulled, and severity of
depilation at hair pulling sites
Eight of the nine
patients responded
to haloperidol with
near complete
cessation of hair
pulling. Two patients
discontinued haloperidol
but experienced a
relapse in hair pulling
Sedation
Increased heart rate
Restlessness
Constipation
Reversal of
trichotillomania
with aripiprazole [21]
Aripiprazole Second
generation antipsychotic
Case report of a
32-year old woman
with a 19-year history
of TTM, co-morbidity
of major depression and
mild/moderate OCD
Aripiprazole started
at 15 mg/day, continued
till hair pulling cessation
Severity of TTM,
cessation of hair
pulling, monitor
for relapse
The patient reported
a reduction of hair
pulling by day 10 and
complete cessation
by day 21. Complete
cessation continued for
24 months with no
recurrence
Not stated
Resistant trichotillomania
and risperidone [54]
Risperidone Second
generation antipsychotic
Case report of a
22-year-old woman
with antisocial
personality disorder
and comorbid TTM
Risperidone treatment
started and dosage
was increased to 4 mg/day
TTM symptoms’
cessation
Patient reported
complete cessation
of TTM symptoms
for 8 months
Not stated
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Trichotillomania clinical studies and neurobiology review 181Synthetic D9-Tetrahydrocannabinol (D9-THC)
As previously stated, there has been interest in targeting gluta-
matergic dysfunction in the treatment of TTM. D9-THC, a
phytocannabinoid constituting the major active ingredient of
cannabis, interacts with the endocannabinoid system (through
the cannabinoid CB1 and CB2 receptors) that serves as a neu-
romodulator for a myriad of neurotransmitters, including glu-
tamate. Grant et al. [47] have shown that dronabinol, a
synthetic THC, targets the overproduction of glutamate that
is implicated in the symptoms seen in TTM. THC binds to
cannabinoid receptors (CB1Rs) inhibiting the release of gluta-
mate onto CA1 neurons. The activation of CB1 receptor has
been shown to inhibit glutamate-induced excitotoxicity, and
it is believed that in trichotillomania there is a loss of function
in these receptors. Hence, Grant et al. examined the effect of
dronabinol in the management of TTM [47]. In a 12-week
open-label study, researchers hypothesized that dronabinol
would reduce hair pulling behavior in TTM patients.
Statistically signiﬁcant improvements were observed for
TTM scores. Grant and colleagues also included neurocogni-
tive testing to determine any adverse effects of THC on mem-
ory, attention, executive function, and psychomotor speed.
The results showed that there were no signiﬁcant effects on
any of these cognitive factors. Targeting CB1 receptors repre-
sents a newer area of research that should be further explored.
Based on the results from Grant et al. [47] more research is
needed to elucidate the possible efﬁcacy of the cannabinoid
agonist, dronabinol or other analogs, in the treatment of
TTM. Longer duration of the studies is also needed to assess
long term effects of these compounds.
Antidepressant agents
The use of antidepressants in the treatment of TTM stems
from the belief that TTM is linked to OCD due to the presen-
tation of repetitive symptoms [7]. Some authors believe that
TTM should be classiﬁed with OCD along with other disor-
ders that have similar behavioral symptoms [7]. In a 12-
week, open-label, ﬂexible-dose study, Gadde et al. reported a
signiﬁcant decrease in the trichotillomania severity in patients
treated with the SSRI, escitalopram [48]. A similar study was
previously conducted by Stein et al. [49], whereby a 12-week,
open-label trial was performed using the SSRI, citalopram,
in TTM patients. The study reported a signiﬁcant reduction
in TTM severity as well as in comorbid depression. On the
other hand, a 31-week, double blind, placebo-controlled cross-
over trial showed no statistically signiﬁcant effect of ﬂuoxetine
on TTM severity [50].
Despite the conﬂicting results with the SSRI antidepressant
trials, a few scattered case studies report positive response of
individual TTM patients to antidepressant therapy. A case
report involving a 35-year-old with an 8-year history of
TTM had been treated with psychotherapy, pharmacotherapy,
and hypnosis. Previous medication included clomipramine,
sertraline, paroxetine, citalopram, escitalopram, klonopin,
aripiprazole, and 4 trials of ﬂuoxetine. Bupropion XL, a dopa-
mine and norepinephrine reuptake inhibitor, was started and
within 2 weeks of starting treatment, the patient reported com-
plete cessation of hair pulling [51]. Similarly, a 17-year-old girl
with TTM initially underwent psychotherapy for the treatmentwith no avail. She was prescribed clomipramine, a tricyclic
antidepressant, and after 2 weeks reported the ability to resist
the urge to pull out her hair [52].
Although antidepressants were once thought to be the ﬁrst
line of choice in treating the TTM, research has shown that
antidepressants do not offer consistent positive results.
However, SSRIs might be useful in the management of comor-
bid depression or anxiety symptoms associated with TTM. A
recent random effect meta-analysis study conducted by
McGuire et al. [53] examined the efﬁcacy of SSRI therapy in
11 randomized controlled trials. The study reported a moder-
ate treatment pooled effect size of SSRIs. Current research is
focused on examining the potential effectiveness of other drug
classes with different mechanisms of action.
Antimanic mood-stabilizing drugs
Since TTM was previously classiﬁed as an impulse control dis-
order and does not currently have any FDA-approved treat-
ment option, a wide variety of medications are used to
attempt to treat it [54]. Among these medications lithium is
the most commonly used antimanic. An early study reported
that, in an uncontrolled trial of lithium, 8 out of 10 patients
showed decrease in hair pulling and a tendency for hair
regrowth [55]. Sharma and Corpse [54] reported two case
reports of effective use of lithium in TTM patients. A case
report of a 26-year-old pregnant woman with TTM had expe-
rienced symptom exacerbations postpartum. Lithium was ini-
tiated and within 4 days the patient reported a decrease in
the urge to pull out her hair. Another case report of a 27-
year-old woman (at 24 week gestation), with bipolar II disor-
der and a history of TTM was given lithium and reported a
reduction in the urge to pull hair.
The limited reported studies described above do not pro-
vide concrete evidence of the effectiveness of antimanic drugs
in TTM. Additionally, the existence of comorbid bipolar disor-
der in these cases suggests that positive ﬁndings might be
attributed to the mood stabilizing effects of these agents.
Antipsychotic agents
Although many researchers believe TTM is similar to OCD,
others believe the behavior observed in TTM resembles tics
seen in Tourette’s syndrome [19]. Both hair pulling and tics
occur unconsciously and do not respond well to SSRIs. Due
to the fact that Tourette’s syndrome responds well to antipsy-
chotic medications, researchers believe TTM might too. So far,
trials have been concluded with the antipsychotics olanzapine,
haloperidol, and aripiprazole. In a 12-week, double-blind,
placebo-controlled trial researchers tested the efﬁcacy of olan-
zapine, a potent antagonist of serotonin, dopamine, histamine,
and alpha1-adrenergic receptors, in the treatment of TTM.
Olanzapine was shown to be signiﬁcantly superior to the pla-
cebo in reducing TTM severity score [20]. The same research
group conducted an open trial of haloperidol in the treatment
of TTM. Haloperidol is a high potency ﬁrst generation
antipsychotic that blocks postsynaptic mesolimbic dopaminer-
gic D1 and D2 receptors [19]. Van Ameringen et al. conducted
a study on nine TTM patients. Six patients who had a partial
response or no response to SSRIs were treated with haloperi-
dol and an SSRI. The three other patients only received
182 J. Johnson and A.T. El-Alfyhaloperidol. Eight of the nine patients responded to haloperi-
dol with near complete cessation of hair pulling. Two patients
eventually discontinued haloperidol and experienced a relapse
in hair pulling [19]. Only one case study reported complete ces-
sation of hair-pulling, with no relapse up to 24 months. The
case was of a 32-year old woman with a 19-year history of
TTM with co-morbidity of major depression and mild/moder-
ate OCD. The patient was administered aripiprazole (a second
generation antipsychotic that serves as a partial agonist at D2
and 5-HT1A receptors and antagonist activity at 5-HT2A
receptors) for the treatment of TTM. The patient reported a
reduction of hair pulling by day 10 and complete cessation
by day 21. Complete cessation continued for 24 months with
no recurrence [21]. Another case reported a 22-year-old
woman with antisocial personality disorder and comorbid
TTM treated with risperidone. Risperidone is another second
generation antipsychotic agent that acts as a selective
monoaminergic antagonist with a strong afﬁnity for serotonin
Type 2 (5-HT2) receptors and a slightly weaker afﬁnity for
dopamine Type 2 (D2) receptors. A decrease in hair pulling
was seen after 4 weeks of treatment. Complete cessation of
TTM symptoms was reported and continued for 8 months fol-
lowing increasing the risperidone dose [54]. As evident, the cur-
rently available literature evaluating the use of antipsychotics
in TTM is scattered, with a few isolated case reports and a cou-
ple of trials that suffer from small sample size as a major short-
coming. As such it is hard to reach any conclusions regarding
the effectiveness of this class of drugs and its potential contri-
bution to the therapeutic management of TTM.
Table 1 summarizes the details and results of the available
clinical trials and case reports reviewed. Based on these studies
it is apparent that there is still no consistent treatment option
available for TTM. Researchers have explored a variety of
drug classes, with different mechanisms of action in an attempt
to provide an effective treatment strategy. From stimulants to
anti-depressants to an opioid antagonist, future studies are
warranted, especially that there are several problems associ-
ated with many of the currently available trial studies. A few
of these problems are, of course, the scarcity of trials, the small
sample sizes, inconsistencies in inclusion criteria (concurrent
psychotherapy and pharmacotherapy), short trial duration,
and lack of follow-up data. Furthermore, as seen in Table 1,
many of these pharmacotherapies employed so far are associ-
ated with adverse effects that impede patient’s compliance,
especially for long term usage. Based on the limited data at
hand, it seems that NAC, dronabinol, and naltrexone might
provide potential treatment options for TTM. However, more
clinical trials with large sample sizes are needed in order to
conclusively study their effectiveness. Although previous stud-
ies showed statistically signiﬁcant results, it remains to be seen
whether that would hold true in a larger population.Conclusions
Trichotillomania (TTM) is a disabling disorder in which indi-
viduals have the urge to pull their hairs out. Unfortunately,
TTM is under recognized and there is a lack of research and
funding devoted to the disorder. Most of the research of
TTM has been focused on whether it should be considered
an OCD subset instead of aiming to explain and treat the dis-
order. Our current lack of understanding of the etiology andpathophysiology of the disorder certainly hinders the efforts
for proper treatment, let alone the proper classiﬁcation of
the disorder. The never ending debate of TTM classiﬁcation
as an impulse versus OCD necessitates further insights into
the neurobiology of the disorder. Future research should focus
on utilizing advanced imaging technology, coupled to experi-
mental animal models, for mechanistic investigation of neural
circuits involved in the disorder. Additional studies that
explore the role of various neurotransmitter pathways in the
etiology and pathophysiology of the disorder are certainly
warranted. The serotonergic, dopaminergic, and glutamatergic
pathways are among the top candidates to be investigated, and
the role of genes of these pathways in the pathogenesis of TTM
needs to be examined.
So far, behavioral approaches seem to be the ﬁrst line of
therapy for most patients. The use of NAC as a ﬁrst line phar-
macological treatment, particularly in adult TTM patients is
increasing. However, the use of pharmacotherapy, either
alone, or as add-on treatments, needs to be further investi-
gated. Currently, the various pharmacological approaches
adopted for TTM lack solid clinical evidence because of
unavailability of controlled studies with suitable sample size.
In addition, effectiveness seems to be highly individualized,
and might be hindered by the side effect proﬁle associated with
these medications. Accordingly, controlled trials are needed to
assess the effectiveness of this approach as well as to compare
it with behavioral alternatives.
Finally, it is imperative to bring awareness to TTM and for
it to be recognized as a debilitating disorder. Not only do indi-
viduals struggle emotionally but also physically, as they have
to endure the embarrassment and shame of hair loss. Those
with TTM often resort to social isolation due to embarrass-
ment, and better understanding and awareness of the disorder
is certainly the ﬁrst step toward helping these patients.
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